Cantitate/Preț
Produs
Total produse
Vezi coșul
Resistance of Cancer Cells to CTL-Mediated Immunotherapy de Benjamin Bonavida

Resistance of Cancer Cells to CTL-Mediated Immunotherapy: Resistance to Targeted Anti-Cancer Therapeutics, cartea 7

Editat de Benjamin Bonavida, Salem Chouaib
en Limba Engleză Hardback – 30 iun 2015
This comprehensive volume explores the latest research on the mechanisms of resistance in cancer cells to CTL-mediated immunotherapy. Chapter topics discuss cell-mediated immunity as the result of cytotoxic T-lymphocytes (CTL) directed specifically against cancer cells. In addition, the volume reviews how CTL mediate the cytotoxic activity, in large part, by the indication of apoptosis; hence, tumor cells develop anti-apoptotic mechanisms and thereby, resist CTL-induced apoptosis. In order for CTL-mediated antitumor immunotherapy to be effective, it is essential that agents directed against the resistant tumor cells sensitized cancer cells for CTL-mediated apoptosis. Examples of such agents discussed in the volume include are HDAC inhibitors, proteasome inhibitors, Bcl-2 family inhibitors, PARP, antibodies, and more.
Citește tot Restrânge

Din seria Resistance to Targeted Anti-Cancer Therapeutics

  • 5% Current Applications for Overcoming Resistance to Targeted Therapies
    Preț: 70357 lei
  • 5% Resistance to Proteasome Inhibitors in Cancer: Molecular Mechanisms and Strategies to Overcome Resistance
    Preț: 108479 lei
  • 5% Resistance to Tyrosine Kinase Inhibitors
    Preț: 107388 lei
  • 5% Resistance to Targeted Therapies Against Adult Brain Cancers
    Preț: 107799 lei
  • 5% Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy: Targeted Therapies to Reverse Resistance
    Preț: 107120 lei
  • 5% TRAIL, Fas Ligand, TNF and TLR3 in Cancer
    Preț: 108088 lei
  • 5% Resistance to Molecular Therapies for Hepatocellular Carcinoma
    Preț: 107171 lei
  • 5% Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
    Preț: 107708 lei
  • 5% Resistance to Targeted Therapies in Breast Cancer
    Preț: 107388 lei
  • 5% Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
    Preț: 82400 lei
  • 5% Resistance to Ibritumomab in Lymphoma
    Preț: 70144 lei
  • 5% Cancer Stem Cell Resistance to Targeted Therapy
    Preț: 70037 lei
  • 5% Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance
    Preț: 107171 lei
  • 5% Resistance to Targeted Therapies in Lymphomas
    Preț: 69785 lei
  • 5% Resistance to Targeted Therapies in Multiple Myeloma
    Preț: 100382 lei
  • 5% Resistance to Targeted ABC Transporters in Cancer
    Preț: 70894 lei
  • 5% Resistance to Photodynamic Therapy in Cancer
    Preț: 70662 lei
  • 5% Resistance to Immunotoxins in Cancer Therapy
    Preț: 70662 lei
  • 5% Resistance to Aromatase Inhibitors in Breast Cancer
    Preț: 70859 lei
  • 5% Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy
    Preț: 70322 lei

Preț: 71198 lei

Preț vechi: 74946 lei
-5% Nou

Puncte Express: 1068
Preț estimativ în valută:
13626€ • 14154$ • 11318£

Carte tipărită la comandă

Livrare economică 03-17 februarie 25

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783319178066
ISBN-10: 3319178067
Pagini: 333
Ilustrații: XIX, 353 p. 38 illus., 27 illus. in color.
Dimensiuni: 155 x 235 x 22 mm
Greutate: 0.69 kg
Ediția:2015
Editura: Springer International Publishing
Colecția Springer
Seria Resistance to Targeted Anti-Cancer Therapeutics

Locul publicării:Cham, Switzerland

Public țintă

Research

Cuprins

1 Resistance of Cancer Stem Cells to Cell-mediated Immune Responses .-2 Role of Co-inhibitory Molecules in Tumor Escape from CTL attack.-3 Role of the Non-classical HLA Class I Antigens for Immune Escape .-4 Integrins: Friends or Foes of Antitumor Cytotoxic T Lymphocyte Response.-5 Cytotoxic T Lymphocytes and Their Granzymes: An Overview.-6 Hypoxia: A Formidable Saboteur of the Anti-tumor Response.-7 Mechanisms and Modulation of Tumor Microenvironment-Induced Immune Resistance .-8 Evasion of Cytotoxic Lymphocyte and Pulmonary Macrophage Mediated Immune Responses in Lung Cancer.-9 Sensitization of Immune-Resistant Tumor Cells to CTL-mediated Apoptosis via Interference at the Dysregulated NF-κB/Snail/YY1/PI3K/RKIP/PTEN Resistant Loop.-10 Overcoming Cancer Cell Resistance to Death Receptor Targeted Therapies.-11 Pancreatic Cancer Resistance to TRAIL Therapy: Regulators of the Death Inducing Signaling Complex.-12 Resistance of Carcinoma Cells to CTL-mediated Immunotherapy.-13 Cancer Induced Immunosuppression and its Modulation by Signal Inhibitors.-14 Quality of CTL Therapies: A Changing Landscape.

Notă biografică

Benjamin Bonavida, Ph.D., is Professor, UCLA David Geffen School of Medicine for the Department of Microbiology, Immunology & Molecular Genetics. He is also Member, Department of Defense Congressionally Directed Medical Research Program, Member, National Cancer Institute SPORE Program, Member, International Scientific Advisory Board of the Israel Cancer Research Foundation, among other accomplishments. He is currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. He has published over 450 papers and reviews, has received more than 7,980 citations, and has edited four Springer volumes.
Salem Chouaib, Ph.D., is Head, Cancer Immunology Division at Institut Gustave Roussy. His research focuses on augmenting cytotoxic T cell immunity and studies how tumors evade the immune system. Dr. Chouaib has published more than 239 scientific papers and reviews, and has received more than 5,490 citations.

Textul de pe ultima copertă

This book, written by leading investigators, brings together the latest knowledge about key aspects of the most rapidly progressing fields of tumor escape and tumor resistance to CTL. Readers will benefit from a collection of outstanding surveys that cover some factors regulating resistance to CTL cytotoxicity, the influence of tumor microenvironment, and the resistance to death ligands, mediated apoptosis, and means to reverse resistance. This remarkable volume also emphasizes the future directions that may lead to the design of more innovative, refined,  and integrative immunotherapies to target tumor plasticity and heterogeneity, and help to overcome the inherent limitations of current treatments. By providing a broad scope of innovative concepts in the burgeoning field of cancer biology and immunotherapy, this volume will be of exceptional interest and a valuable reference for scientists, clinicians, health professionals, and biopharmaceutical companies working in the field of cancer immunotherapy.
 

Caracteristici

Explores the inhibition of CTL-cytotoxic function by tumor-derived T-regulatory cells, along with the inhibition of cytotoxic function by tumor induction of hypoxia Discusses the overexpression of transcription factors that regulate resistance Appeals to cancer researchers, biologists and immunologists